Posted by Michael Wonder on 07 Nov 2018
AbbVie announces Humira (adalimumab) global patent license with Momenta
6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product.
Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie's intellectual property relating to Humira in the United States and in various other countries around the world in which AbbVie has intellectual property:
- Momenta's U.S. license will begin on 20 November 2023, and will not be accelerated by the entry of companies who have already taken a license.
- In the European Union, Momenta can launch upon approval from the European Medicines Agency.
